There are 413 resources available
247P - Efficacy of therapy directed against PI3K and cyclin inhibitors based on the location of PI3K mutations
Presenter: Pablo Torres-Mozas
Session: Poster viewing and lunch
248P - Systemic treatment strategies following progression on CDK4/6 inhibitors in advanced breast cancer: a single-center real-world experience
Presenter: Pierluigi di Mauro
Session: Poster viewing and lunch
249P - A retrospective review of patients receiving trastuzumab deruxtecan across five centres in Ireland with a subgroup analysis of patients with CNS involvement assessing response in the CNS
Presenter: Catherine Murphy
Session: Poster viewing and lunch
250P - Liver Toxicity (LT) in patients (pts) with ER-positive HER2-negative Metastatic Breast Cancer (MBC) treates with first-line Cyclin-Dependent Kinase 4/6 inhibitors (CDKi)
Presenter: KREINA VEGA CANO
Session: Poster viewing and lunch
251P - The Effect of Hormone Receptor Positive Percentage On Treatment Response And Prognosis In HR+ HER2- Metastatic Breast Cancer Receiving CDK 4/6 Inhibitor + Endocrine Treatment
Presenter: Merve Keskinkilic
Session: Poster viewing and lunch
252P - Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 Negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study
Presenter: Seda Kahraman
Session: Poster viewing and lunch
253P - Immunopheresis to Remove Soluble TNF Receptors as a Novel Immunotherapy for Patients with Advanced Breast Cancer
Presenter: Piotr Wysocki
Session: Poster viewing and lunch
254P - The invasive lobular cancer of the breast (ILC): a collection of clinical and pathological data in patients with (non-)metastatic breast cancer (BC)
Presenter: Toni Ljubicic
Session: Poster viewing and lunch
255TiP - AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization.
Presenter: Francois Duhoux
Session: Poster viewing and lunch
256TiP - TACTIVE-E: phase 1b study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with everolimus in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
Presenter: Alexander Philipovskiy
Session: Poster viewing and lunch